Sun Pharmaceutical Industries rose 2.75% to Rs 916.20 at 11:48 IST on BSE after the company's foreign unit Taro Pharmaceutical Industries reported good results for the quarter ended 30 September 2013.
Meanwhile, the BSE Sensex was down 31.88 points, or 0.11%, to 27,836.75.
On BSE, so far 1.70 lakh shares were traded in the counter, compared with an average volume of 2.04 lakh shares in the past one quarter.
The stock hit a high of Rs 932 so far during the day, which is also a record high for the counter. The stock hit a low of Rs 898 so far during the day. The stock hit a 52-week low of Rs 552.50 on 14 March 2014.
The stock had outperformed the market over the past one month till 7 November 2014, rising 6.55% compared with 6.08% rise in the Sensex. The scrip had also outperformed the market in past one quarter, rising 17.46% as against Sensex's 8.91% rise.
The large-cap company has an equity capital of Rs 207.12 crore. Face value per share is Re 1.
Sun Pharmaceutical Industries' US-listed Israeli unit Taro Pharmaceutical Industries (Taro)'s net profit jumped 48.9% to $143.4 million on 22.2% growth in net sales to $250.8 million in Q2 September 2014 over Q2 September 2013. Operating income increased $40 million to $160.3 million, or 63.9% of net sales in Q2 September 2014, compared to 58.6% of net sales in Q2 September 2013.
Taro Pharmaceutical Industries is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
Sun Pharmaceutical Industries will announce Q2 results on 13 November 2014. The company reported consolidated net profit of Rs 1390.51 crore in Q1 June 2014 as compared to net loss of Rs 1276.10 crore in Q1 June 2013. Net sales rose 12.8% to Rs 3926.85 crore in Q1 June 2014 over Q1 June 2013.
Sun Pharmaceutical Industries is an international specialty pharmaceutical company.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
